GlassScriptPhysician profile
Catherine Sekansky
NPI 1497980171
$28,465.57
in general payments reported to CMS, 2019-2025
47 companies · $7,630 in 2025
The $7,630 reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,771 · 2022: $4,705 · 2023: $4,959 · 2024: $6,401 · 2025: $7,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,929.80 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,403.57 | 2021-2025 | Tepezza, Repatha, Repatha |
| Novo Nordisk INC | $2,961.51 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amneal Pharmaceuticals LLC | $2,511.71 | 2021-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,635.22 | 2021-2025 | Jardiance, Tradjenta |
| Xeris Pharmaceuticals, INC. | $1,361.28 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $1,344.81 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,198.95 | 2022-2025 | |
| Esperion Therapeutics, INC. | $1,120.22 | 2023-2025 | Nexletol, Nexlizet |
| Horizon Therapeutics Plc | $934.99 | 2021-2023 | Tepezza |
| Chiesi USA, INC. | $923.70 | 2024-2025 | Mycapssa |
| Lilly USA, LLC | $872.34 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $813.94 | 2024-2025 | Veozah |
| Mannkind Corporation | $760.13 | 2021-2025 | Afrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $734.91 | 2021-2024 | Trulance |
| Amarin Pharma, INC. | $656.58 | 2021-2023 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $630.52 | 2024-2025 | Yorvipath |
| Regeneron Healthcare Solutions, INC. | $543.47 | 2021-2023 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $481.03 | 2021-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $414.74 | 2021-2023 | |
| Amryt Pharma Holdings LTD | $395.17 | 2022-2023 | Mycapssa, Myalept |
| Genzyme Corporation | $296.50 | 2025 | |
| Almatica Pharma LLC | $277.60 | 2024-2025 | Teriparatide, Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $249.97 | 2021-2024 | |
| Corcept Therapeutics | $237.19 | 2021-2025 | Korlym |
| Merck Sharp & Dohme LLC | $221.49 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $205.15 | 2021-2023 | Somatuline Depot |
| Dexcom, INC. | $174.34 | 2021-2023 | Dexcom G6 Transmitter |
| Intra-Sana Laboratories | $127.59 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Tolmar Pharmaceuticals, INC. | $126.61 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $101.37 | 2024-2025 | Zenpep |
| Radius Health, INC. | $97.74 | 2021 | |
| Insulet Corporation | $94.25 | 2021-2023 | Omnipod |
| Vistapharm, INC. | $88.21 | 2021 | |
| Alvogen INC | $65.26 | 2021-2025 | Teriparatide |
| Amphastar Pharmaceuticals, INC. | $63.65 | 2023-2024 | Baqsimi |
| Takeda Pharmaceuticals U.S.A., INC. | $55.66 | 2021 | |
| Cequr Corporation | $47.80 | 2023-2024 | Cequr Simplicity |
| Zealand Pharma US, INC. | $42.16 | 2021 | |
| Ibsa Pharma INC. | $24.90 | 2022 | |
| Abbott Laboratories | $24.13 | 2022 | |
| Biomarin Pharmaceutical INC. | $24.13 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $23.65 | 2022 | |
| Tolmar, INC. | $22.89 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $22.35 | 2021 | |
| Travere Therapeutics, INC. | $21.15 | 2023 | Cholbam |
| Pfizer INC. | $17.22 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Sekansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.